Table 2.

Cardiovascular adverse event reporting in combination with known cardiotoxic anticancer agents from 2010 to 2020

Therapy	# CV/total reported events	% of reported events	Adjusted OR	95% CI	P value
Taxanes+any of the four agents	2944/16 458	17.9	Ref	–	–
Taxanes	6206/54 332	11.4	0.50	0.35 to 0.73	0.004
Taxanes+anthracyclines	485/3341	14.5	Ref	–	–
Taxanes			0.55	0.35 to 0.84	0.007
Taxanes+HER2 Neu inhibitors	1559/9273	16.8	Ref	–	–
Taxanes			0.39	0.26 to 0.58	<0.001
Taxanes+tyrosine kinase inhibitors	69/655	10.5	Ref	–	–
Taxanes			3.71	0.87 to 15.9	0.08
Taxanes+checkpoint inhibitor	831/3189	26.1	Ref	–	–
Taxanes			0.53	0.22 to 1.26	0.15
Vinca alkaloids+any of the four agents	2115/15 445	13.7	Ref	–	–
Vinca alkaloids	1209/10 646	11.4	0.79	0.73 to 0.85	<0.001
Vinca alkaloids+anthracyclines	1759/12 953	13.6	Ref	–	–
Vinca alkaloids			0.80	0.74 to 0.87	<0.001
Vinca alkaloids+HER2 Neu inhibitors	175/1139	15.4	Ref	–	–
Vinca alkaloids			0.58	0.49 to 0.70	<0.001
Vinca alkaloids+tyrosine kinase inhibitors	136/1032	13.2	Ref	–	–
Vinca alkaloids			0.86	0.71 to 1.05	0.14
Vinca alkaloids+checkpoint inhibitor	45/321	14.0	Ref	–	–
Vinca alkaloids			0.86	0.62 to 1.19	0.36

Total and cardiovascular adverse event reporting are shown. The OR for cardiovascular adverse event reporting (adjusted for age, gender, year of reporting, reporting source, need for hospitalisation, mortality) is shown as compared with any of the combinations.

CV, cardiovascular.